

Bain Capital to acquire Mitsubishi Tanabe Pharma Corporation for \$3.3 B

06 February 2025 | News

Transaction is expected to close in the third guarter of 2025



Bain Capital, a leading global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The investment is being led by Bain Capital's Private Equity teams in Asia and North America together with the firm's Life Sciences team and values the business at approximately 510 billion JPY (\$3.3 billion).

Founded in 1678, Tanabe Pharma is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. Through the discovery and development of innovative drugs that address unmet medical needs, MTPC focuses on several priority therapeutic areas, including immunology & inflammation, vaccines, central nervous system (CNS), diabetes and metabolic disease. MTPC employs over 5,000 people globally.

As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development, licensing activities, enhanced R&D productivity, commercialisation and strategic acquisitions.

Bain Capital's global Healthcare platform has deep experience supporting the growth and innovation of global pharmaceutical companies including Aiolos Bio (now part of GSK), Avistone Pharmaceuticals, Cardurion Pharmaceuticals, Cerevel Therapeutics (now part of AbbVie), Kailera Therapeutics, Stada, Tenacia Biotechnology, and Timberlyne Therapeutics. The firm is also a leading investor and partner to businesses across Japan, with more than 70 investment professionals who have made over 37 investments since establishing its Tokyo office in 2006.

The transaction is expected to close in the third quarter of 2025 and is subject to customary closing conditions, regulatory clearance and shareholder approvals.